Posted by Michael Wonder on 01 Aug 2025
Reimbursement for oral Fabry disease drug Galafold expanded to first-line treatment
1 August 2025 - Handok's Fabry disease treatment, Galafold (migalastat), will have its insurance coverage criteria expanded to include first-line therapy starting this month.
Previously, Galafold was eligible for insurance coverage for patients aged 16 years or older who had received enzyme replacement therapy via intravenous infusion for at least 12 months.
